louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01327170: Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy
Official title: Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Central Serous Chorioretinopathy
Lead sponsor: Federal University of São Paulo
Sponsor class: OTHER
First posted: 2011-04-01
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to evaluate safety and therapeutic response to micropulse diode 810nm laser treatment in patients with chronic central serous chorioretinopathy.

Detailed description: Most of the cases of central serous chorioretinopathy (CSC) recur spontaneously within three months of disease. After 3 months without resolution of acute CSC or in chronic CSC, continuous wave laser photocoagulation or photodynamic therapy should be considered. Direct threshold continuous photocoagulation treatment can shorten the duration of the serous detachment, but it is not appropriate for juxtafoveal or subfoveal leakage point.Subvisible photocoagulation potentially localizes and decreases chorioretinal thermic burn. Subthreshold diode micropulse (SDM) laser using a 810nm diode laser may spare the damage to the neural retina by raising the temperature of the RPE to just below the protein-denaturation threshold so that the thermal wave that reaches the neural retina is insufficient to cause neither damage nor clinically visible end-point. This therapeutic laser modality offers the possibility to minimize the iatrogenic retinal lesion.

Eligibility criteria: Inclusion Criteria:

* Chronic active central serous chorioretinopathy lasting more than 6 months
* Leakage at fluorescein angiogram

Exclusion Criteria:

* Opacities of the clear refractive media of the eye
* Any intraocular surgery within the 6 months prior to study entry
* Prior vitrectomy

Primary outcomes:
measure: Best corrected visual acuity
timeFrame: 6 months
Secondary outcomes:
measure: Macular subretinal fluid
timeFrame: 6 months
measure: Leakage at fluorescein angiogram
timeFrame: 6 months
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Federal University of São Paulo
Study officials:
affiliation: Federal University of São Paulo
name: Fernanda P Magalhaes, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02901470: Observational Study of the Incidence of Pressure Ulcers on the Help Support of Prevention of Bedsores POLYAIR®
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pressure Ulcer
Lead sponsor: Centre Hospitalier Universitaire de Nīmes
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 98
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Persons who are hospitalized in CHU of Nîmes with high risk of sores (Norton \<9)

Brief summary: The support of help to the prevention of sores include a big diversity of devices. The clinical experiment of these support comes up against the problem of the large number of factors participants in the genesis of bedsores. Nevertheless, it seems to be interesting to estimate the incidence of bedsores in these supports, with control of other factors


Eligibility criteria: Inclusion Criteria:

* Norton Index \<9,
* No sores in ischiatic zone,
* Sitting position not less than 2 hours per day

Exclusion Criteria:

* Sores in ischiatic zone,
* Sitting position \>2 hours per day

Primary outcomes:
measure: Incidence of sores in ischiatic zone
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Nîmes
country: France
facility: CHU Nîmes
state: Gard
Study officials:
References:
Clinical trial NCT05546970: Efficacy of the Transversus Abdominis Plane Block on Analgesia After Cephalic Duodeno-pancreatectomy
Official title: Efficacy of the Transversus Abdominis Plane Block (TAP-Block) on Analgesia After Cephalic Duodeno-pancreatectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatic Neoplasms
Keywords: Neoplastic Disease
Pancreatic neoplasia
Pancreatic Neoplasms
Transversus Abdominis Plane Block
TAP-Block
Cephalic duodeno-pancreatectomy
Lead sponsor: University Hospital, Strasbourg, France
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Major subject (≥18 years of age) operated at HUS for cephalic duodeno-pancreatectomy between 01/01/2018 and 01/04/ 2022

Brief summary: Pancreatic duodenectomy is one of the treatments offered to patients with neoplastic disease of the pancreas. In France, in 2018, 14,000 duodeno-pancreatectomies were performed, including 140 at the Hautepierre hospital at the Strasbourg University Hospital. Pancreaticoduodenectomy is a major surgery, causing significant postoperative pain that should be minimized through multimodal analgesia involving in particular locoregional anesthesia. Since 2019, the recommendations of the ERAS company concerning ERAS (Improved Rehabilitation After Surgery) after pancreaticoduodenectomy recommend the establishment of thoracic epidural analgesia in order to limit postoperative pain. When there is a contraindication to the placement of a thoracic epidural, in particular due to arterial and/or venous vascular reconstructions requiring potential perioperative curative anticoagulation, the administration of local anesthetic by pericatricial catheter is recommended. recommended. The Transversus Abdominis Plane (TAP) block has proven analgesic efficacy, safety and harmlessness in colorectal surgery.


Eligibility criteria: Inclusion criteria:

* Major subject (≥18 years of age)
* Subject operated at HUS for cephalic duodeno-pancreatectomy between 01/01/2018 and 01/04/ 2022.
* Subject who has not expressed an objection to the reuse of their data for scientific research purposes.

Exclusion Criteria:

* Subject having expressed his/her opposition to participate in the study
* Admission in intensive care unit after the operation
* Morphine treatment at home
* Drug addiction, weaned or not

Primary outcomes:
measure: Efficacy of the echo-guided TAP Block on analgesia
timeFrame: Morphine consumption in the first 24 postoperative hours
Secondary outcomes:
Other outcomes:
Locations:
city: Strasbourg
country: France
facility: Service d'Anesthésie, Réanimation et Médecine péri-Opératoire - CHU de Strasbourg - France
Study officials:
References:
Clinical trial NCT01489670: Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Glaucoma, Open-Angle
Ocular Hypertension
Lead sponsor: Allergan
Sponsor class: INDUSTRY
First posted: 2011-12-12
Enrollment: 387
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with primary open-angle glaucoma or ocular hypertension

Brief summary: This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of primary open-angle glaucoma or ocular hypertension
* Lumigan® 0.01% prescribed either as monotherapy or adjunctive to beta-blocker therapy

Exclusion Criteria:

* None

Primary outcomes:
measure: Intraocular Pressure (IOP) at Baseline
timeFrame: Baseline
measure: Intraocular Pressure (IOP) at Week 12
timeFrame: Week 12
Secondary outcomes:
measure: Physician Evaluation of Efficacy Using a 5-Point Scale
timeFrame: Week 12
measure: Patient Evaluation of Tolerability of Treatment Using a 4-Point Scale
timeFrame: Week 12
measure: Physician Evaluation of Tolerability of Treatment
timeFrame: Week 12
measure: Physician Reported Reasons for Early Discontinuation of Treatment
timeFrame: 12 Weeks
measure: Number of Patients Continuing Treatment After 12 Weeks
timeFrame: Week 12
Other outcomes:
Locations:
city: Bülach
country: Switzerland
state: Zurich
Study officials:
affiliation: Allergan
name: Medical Director
role: STUDY_DIRECTOR
References:
Clinical trial NCT03105570: The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study
Official title: The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Neoplasms
Keywords: breast neoplasms
Mastectomy, Subcutaneous
Areola
Lead sponsor: Peking University People's Hospital
Sponsor class: OTHER
First posted: 2017-04-10
Enrollment: 145
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single Armed, prospective, open label study
Primary purpose: TREATMENT

Brief summary: To balance the oncological safety and cosmetic outcome is the basic principle of modern breast surgery. To preserve the nipple-areolar complex shows attractive cosmetic advantage but concerns regarding local recurrence make the oncological safety of nipple sparing mastectomy a controversial issue. Since the involvement of areolar pigmented skin by cancer is rare compared to that of nipple, we designed the current study to investigate the oncological safety and cosmetic outcome of Areola Sparing Mastectomy.

Detailed description: Primary breast cancer originated from areolae is rare. We hypothesized that nipple and areola are two separate anatomy tissue and have different oncological impact on the treatment of breast cancer. Areola Sparing Mastectomy (ASM) is a innovative procedure that involves of removal of nipple and preservation of areola the pigmented skin of which would improve the cosmetic outcome of mastectomy and lead to a illusion of congenital crater nipple in some patients.

Eligibility criteria: Inclusion Criteria:

* Histologically confirmed invasive or in situ breast cancer.
* cTis-2N0-1M0.
* Indicated for total mastectomy and desire immediate breast reconstruction.

Exclusion Criteria:

* cT3-4 or cN2-N3 breast cancer.
* Retraction of nipple or areola.
* Involvement of subcutaneous layer by cancer on ultrasound or MRI.

Primary outcomes:
measure: Recurrence of areolar area
timeFrame: Five years after initial surgery
Secondary outcomes:
measure: Cosmetic effect of reconstructed breast
timeFrame: 2-4 weeks after surgery; 2 years and 5 years after surgery.
measure: Adverse effect of surgery
timeFrame: 4 weeks after surgery.
measure: Disease free survival
timeFrame: 5 year after surgery
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking University People's Hospital
state: Beijing
Study officials:
affiliation: Peking University People's Hospital
name: Shu Wang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01364870: Effect of TENS for Pain and Function After Total Knee Replacement
Official title: Effect of TENS on Hyperalgesia, Pain With Movement, and Function After TKR
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Unilateral Primary Osteoarthritis of Knee
Primary Osteoarthritis of Knee Nos
Keywords: Knee OA
TENS
Total knee replacement
Knee arthroplasty
total unilateral knee replacement
Lead sponsor: University of Iowa
Sponsor class: OTHER
First posted: 2011-06-03
Enrollment: 317
Sex: ALL
Minimum age (years): 30
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Our primary hypothesis is that TENS decreases pain with movement by reducing hyperalgesia. Minimizing the severe pain experienced during required activities in the immediate postoperative period will promote functional recovery and prevent the development of new chronic pain syndromes.


Eligibility criteria: Inclusion Criteria:

* Primary osteoarthritis of the knee
* Speak English
* Unilateral total knee replacement

Exclusion Criteria:

* No ambulation, assisted or otherwise
* Use of TENS by subject in past 5 yrs
* Current use of TENS by someone else in subject's household
* Stroke or other condition which seriously impairs sensation in legs or ability to follow directions.
* Condition that precludes use of TENS (pacemaker, allergy to nickel, etc.)
* Chronic pain (other than in surgical knee) that is currently being treated or is severe. (Do not exclude for fibromyalgia).

Primary outcomes:
measure: Self-Reported Pain With Movement
timeFrame: 1 day post-op
measure: Self-reported Pain With Walking (From Iowa Gait Test)
timeFrame: 2 days post-op
Secondary outcomes:
Other outcomes:
Locations:
city: Iowa City
country: United States
facility: University of Iowa
state: Iowa
Study officials:
affiliation: University of Iowa
name: Barbara Rakel, PhD, RN
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dindo L, Zimmerman MB, Hadlandsmyth K, StMarie B, Embree J, Marchman J, Tripp-Reimer T, Rakel B. Acceptance and Commitment Therapy for Prevention of Chronic Postsurgical Pain and Opioid Use in At-Risk Veterans: A Pilot Randomized Controlled Study. J Pain. 2018 Oct;19(10):1211-1221. doi: 10.1016/j.jpain.2018.04.016. Epub 2018 May 17.
Clinical trial NCT01077570: An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients
Official title: The Clinical Safety and Effectiveness of Repaglinide in Treatment-naive Type 2 Diabetes Subjects in China. A 16-week Multicentre, Prospective, Open Label, Non-interventional Study.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes
Diabetes Mellitus, Type 2
Lead sponsor: Novo Nordisk A/S
Sponsor class: INDUSTRY
First posted: 2010-03-01
Enrollment: 2033
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients from both general and speciality practice settings who have been deemed appropriate to receive Repaglinide as initial treatment and as part of routine out-patient care by the prescribing physician.

Brief summary: This study is conducted in Asia. The aim of this observational study is, under normal clinical practice conditions, to investigate the clinical safety and effectiveness in Chinese patients with type 2 diabetes who have never received anti-diabetic treatment before.


Eligibility criteria: Inclusion Criteria:

* HbA1c more than 6.5%, no anti-diabetes treatment accepted before entering the study

Exclusion Criteria:

* Subjects who received any anti-diabetic treatment previously
* Known or suspected allergy to trial product(s) or related products.
* Subjects who previously enrolled in this study.
* Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods.

Primary outcomes:
measure: Number of serious adverse drug reactions (SADRs) including major hypoglycaemic (low blood sugar) events
timeFrame: at Visit 2(8 weeks) and visit 3(16 weeks)
Secondary outcomes:
measure: Number of minor hypoglycaemic (low blood sugar) episodes
timeFrame: at Visit 2(8 weeks) and visit 3(16 weeks)
measure: Number of adverse drug reactions (ADRs)
timeFrame: at Visit 2(8 weeks) and visit 3(16 weeks)
measure: Change in HbA1c
timeFrame: after 16 weeks of treatment
measure: Change in fasting blood glucose (FBG)
timeFrame: after 8 and 16 weeks of treatment
measure: Change in postprandial blood glucose (PBG)
timeFrame: after 8 and 16 weeks treatment
Other outcomes:
Locations:
city: Beijing
country: China
state: Beijing
Study officials:
affiliation: Novo Nordisk A/S
name: Global Clinical Registry (GCR, 1452)
role: STUDY_DIRECTOR
References:
Clinical trial NCT00354770: N-Acetyl Cysteine in Trichotillomania
Official title: A Double-Blind, Placebo-Controlled Study of N-Acetyl Cysteine in Trichotillomania
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Trichotillomania
Keywords: Trichotillomania
Hair-pulling
Lead sponsor: University of Chicago
Sponsor class: OTHER
First posted: 2006-07-20
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a 12-week, double-blind study of N-Acetyl Cysteine in the treatment of trichotillomania

Detailed description: The goal of the proposed study is to evaluate the efficacy and safety of N-Acetyl Cysteine (NAC) in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 12 weeks of double-blind NAC or placebo. The hypothesis to be tested is that NAC will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Eligibility criteria: Inclusion Criteria:

* men and women age 18-65;
* current DSM-IV trichotillomania

Exclusion Criteria:

* unstable medical illness;
* history of seizures;
* myocardial infarction within 6 months;
* current pregnancy or lactation, or inadequate contraception in women of childbearing potential;
* any thoughts of suicide;
* lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any other DSM-IV psychotic disorder;
* previous treatment with N-Acetyl Cysteine;
* treatment with investigational medication or depot neuroleptics within 3 months, with fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study baseline;
* 9) diagnosis of asthma

Primary outcomes:
measure: Massachusetts General Hospital Hairpulling Scale
timeFrame: Baseline and final visit after 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: University of Chicago Medical Center
state: Illinois
Study officials:
affiliation: University of Minnesota
name: Jon E Grant, MD, JD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD007662. doi: 10.1002/14651858.CD007662.pub3.
citation: Odlaug BL, Chamberlain SR, Harvanko AM, Grant JE. Age at onset in trichotillomania:clinical variables and neurocognitive performance. Prim Care Companion CNS Disord. 2012;14(4):PCC.12m01343. doi: 10.4088/PCC.12m01343. Epub 2012 Jul 19.
citation: Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009 Jul;66(7):756-63. doi: 10.1001/archgenpsychiatry.2009.60.
Clinical trial NCT03066570: Graded Exposure in Patients With Painful Diabetic Neuropathy
Official title: Graded Exposure in Patients With Painful Diabetic Neuropathy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Painful Diabetic Neuropathy
Diabetic Neuropathies, Painful
Neuralgia, Diabetic
Keywords: Graded Exposure
Quality of Life
Physical Activity
Anxiety
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2017-02-28
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SEQUENTIAL
Intervention model description: Randomized replicated sequential single-case design.
Primary purpose: TREATMENT

Brief summary: Objective: To investigate the effects of a cognitive behavioural intervention targeting specific fears in patients with painful diabetic neuropathy, on physical activity and quality of life.

Detailed description: Intervention: Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.

Main study parameters/endpoints: The purpose of this project is to develop and test a cognitive behavioural intervention targeting specific fears in patients with PDN, in order to increase physical activity and improve QOL.

Eligibility criteria: Inclusion Criteria:

* Patients with type II diabetes mellitus,
* aged \> 18 years who suffer from peripheral polyneuropathy.

Exclusion Criteria:

* Patients with lower limb morbidities other than PDN such as peripheral arterial disease
* severe osteoarthritis, any other neurological disease than PDN or any other disease that may cause pain in the feet and/or damage to the peripheral nervous system (e.g. ulcers).

Primary outcomes:
measure: Quality of Life as measured with Norfolk Quality of Life Questionnaire, Diabetic Neuropathy Version (Norfolk-QOL-DN)
timeFrame: The primary outcome measure will be measured after 8 weeks of treatment with GEXP.
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
state: Limburg
Study officials:
affiliation: charlotte.geelen@mumc.nl
name: Charlotte Geelen, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00215670: Study of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Pegaptanib Sodium in Patients With Exudative Age-Related Macular Degeneration (AMD)
Official title: A Randomized, Double-Masked, Multi-Center Trial of the Safety, Tolerability and Pharmacokinetics of 1 Mg/Eye and 3 Mg/Eye Intravitreal Injections of Pegaptanib Sodium (Anti-Vegf Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients With Exudative Age-Related Macular Degeneration (AMD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Age-Related Macular Degeneration
Keywords: AMD
Macugen
Pharmacokinetics
Age-Related Macular Degeneration
PK
Lead sponsor: Eyetech Pharmaceuticals
Sponsor class: INDUSTRY
Collaborators: name: Pfizer
First posted: 2005-09-22
Enrollment: 125
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objectives of this study are to characterize the safety, tolerability and pharmacokinetics of pegaptanib when given as 1 or 3mg/eye intravitreous injections every 6 weeks for 54 weeks in patients with subfoveal choroidal neovascularization (CNV) secondary to AMD.


Eligibility criteria: Inclusion Criteria:

Best corrected visual acuity in the study eye between 20/40 and 20/320 and better or equal to 20/800 in the fellow eye.

Subfoveal CNV, secondary to AMD, w/ a total lesion size \[including blood, scar/atrophy \& neovascularization\] of less than or equal to 12 disc areas, of which at least 50% must be active CNV.

Patients of either sex, aged greater than or equal to 50 years.

Exclusion Criteria:

Previous subfoveal thermal laser therapy. Any subfoveal scarring or atrophy \& no more than 25% of the total lesion size may be made up of scarring or atrophy.

More than one prior PDT w/ Visudyne is not permitted. Pts may not have rec'd their 1st PDT w/in less than 8 wks or more than 13 wks prior to the BSL angiography/photography for the study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: